文献速递炎症性肠病

炎症性肠病相关污名化的系统综述

Systematic Review: Stigma Associated With Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-11-04

该系统综述检索MEDLINE、Embase和Scopus至2025年9月,分析73项研究,总结炎症性肠病(IBD)污名化的患病率、评估方法、预测因素和结局。感知污名常见,成人患病率高达85.6%,儿童达87%;污名评估方法异质性显著,缺乏标准化量表。污名与焦虑、抑郁、社会隔离、治疗依从性降低及生活质量下降相关。

要点

  • IBD感知污名常见,成人患病率高达85.6%,儿童达87%。
  • 污名评估方法异质性大,缺乏标准化量表。
  • 污名与焦虑、抑郁、社会隔离及治疗依从性降低相关。

核心结论

  • IBD污名化评估方法异质性显著,需要更标准化的研究。
  • 应通过提高公众认知、提供支持和干预增强韧性及应对技能来应对污名。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和Scopus从建库至2025年9月,分析73项报告IBD污名化患病率、评估、预测因素和结局的研究。

主要发现

  • 感知污名常见,成人患病率高达85.6%,儿童达87%。
  • 污名表现为担心被评判、身体意象问题、人际关系困难和工作场所歧视。
  • 实施性污名和内在污名较少被报告。
  • 疾病复杂性和症状频率更高与感知污名水平更高相关。
  • 公众对IBD认知和知识不足导致污名增加。

关键数值与推荐

  • 感知污名患病率:成人高达85.6%,儿童87%。

临床怎么用

  • 临床应关注IBD患者的污名体验,评估焦虑、抑郁和社会隔离。
  • 提高公众对IBD的认知,提供支持和干预以增强患者韧性和应对技能。

局限性

  • 污名评估方法异质性显著,缺乏标准化量表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stigma, including perceived, enacted, and internalised forms, is associated with inflammatory bowel disease (IBD), affecting quality of life, delaying treatment, and impairing social interactions. AIM: To summarise existing data on stigma related to IBD. METHODS: We searched MEDLINE, Embase and Scopus from inception to September 2025 for studies reporting the prevalence, assessment, predictors, and outcome of stigma in IBD. RESULTS: We analysed 73 studies to explore stigma in IBD, its predictors and outcomes. There was significant heterogeneity in the methods of assessment of stigma due to the lack of standardised scales. Perceived stigma is common, with a prevalence rate of up to 85.6% in adults and 87% in children. Stigma manifests with concerns about being judged, body image issues, difficulties in relationships, and workplace discrimination. However, enacted and internal stigma are less frequently reported. Multiple predictors of stigma in IBD have been identified. Greater disease complexity and symptom frequency are associated with higher levels of perceived stigma. Low public awareness and knowledge of IBD contribute to increased stigma. These lead to psychological impacts such as anxiety and depression, social isolation and healthcare challenges, including reduced treatment adherence, ultimately reducing quality of life. CONCLUSION: This highlights the heterogeneity in stigma assessment methods and the need for more standardised research. It also emphasises the importance of addressing stigma through increased awareness, support and interventions aimed at enhancing resilience and coping skills.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Giri S, Harindranath S, Chandnani S, et al. Systematic Review: Stigma Associated With Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 41186070. doi:10.1111/apt.70448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。